Prognosis analysis and 21-gene recurrence score according to TAILORx standard in hormone receptor positive early-stage breast cancer
10.3760/cma.j.issn.1007-631X.2019.09.007
- VernacularTitle: 参照TAILORx标准的21基因复发风险评分与乳腺癌预后的相关性分析
- Author:
Yanna ZHANG
1
;
Yidong ZHOU
1
;
Feng MAO
1
;
Qiang SUN
1
Author Information
1. Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Prognosis;
21-gene assay;
Recurrence score
- From:
Chinese Journal of General Surgery
2019;34(9):771-775
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the association of 21 gene recurrence score(RS)according to TAILORx standard and prognosis of hormone receptor(HR) positive, axillary lymph node negative breast cancer.
Methods:The clinicopathologic data of 558 early breast cancer patients who underwent 21 gene RS testing from May 2012 to Jan 2017 were retrospectively analyzed. RS was subgrouped according to TAILORx standard.Estimates of relapse free survival(RFS) were made from the Kaplan-Meier curves.
Results:In 558 patients, RS≤10, RS 11-25 and RS≥26 groups accounted for 23.1%, 63.6% and 13.3%.After a median follow-up of 38 months, the recurrence ratesin RS≤10, RS 11-25 and RS≥26 groups were 3.3%, 4.5% and 5.4%, respectively. Kaplan-Meier RFS curve showed no significant difference between the 3 groups(P=0.788). The recurrence ratesin RS≤15 group(3.0%) was significantly lower than that in RS≥16 group(5.9%)(P=0.041).
Conclusions:A significant association exists between RS and breast cancer prognosis.It is rational not to give chemotherapy to RS<18 low risk patients according to classical standard.
